Supernus Pharmaceuticals, Inc.
SUPN
Rang in Aktien
#5703
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Aktienkurs
$40.58
Marktkapitalisierung
$2.36B
Veränderung (1 Tag)
1.86%
Veränderung (1 Jahr)
-20.87%
Land
US
Handel Supernus Pharmaceuticals, Inc. (SUPN)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Supernus Pharmaceuticals, Inc. (SUPN)
Anzahl der ausstehenden Aktien zum October 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Supernus Pharmaceuticals, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von October 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Supernus Pharmaceuticals, Inc. (SUPN) von 2026 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
